The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate

被引:57
作者
McLaughlin, N
Annabi, B
Bouzeghrane, M
Temme, A
Bahary, JP
Moumdjian, R
Béliveau, R
机构
[1] UQAM, Hop St Justine, Ctr Cancerol Charles Bruneau, Mol Med Lab, Quebec City, PQ, Canada
[2] Univ Quebec, Dept Chim Biochim, Oncol Mol Lab, Montreal, PQ H3C 3P8, Canada
[3] Tech Univ Dresden, Med Fac Carl Gustav Carus, Inst Immunol, Dresden, Germany
[4] Univ Montreal, Ctr Hosp, Dept Radiooncol, Montreal, PQ H3C 3J7, Canada
[5] Univ Montreal, Ctr Hosp, Serv Neurochirurg, Dept Chirurg, Montreal, PQ H3C 3J7, Canada
关键词
human glioma; radiotherapy; Survivin; RhoA; EGCg; green tea;
D O I
10.1016/j.brainres.2005.10.009
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction: Glioblastoma multiforme's (GBM) aggressiveness is potentiated in radioresistant tumor cells. The combination of radiotherapy and chemotherapy has been envisioned as a therapeutic approach for GBM. The goal of this study is to determine if epigallocatechin-3-gallate (EGCg), a green tea-derived anti-cancer molecule, can modulate GBMs' response to ionizing radiation (IR) and whether this involves mediators of intracellular signaling and inhibitors of apoptosis proteins. Material and methods: U-87 human GBM cells were cultured and transfected with cDNAs encoding for Survivin, RhoA or Caveolin-1. Mock and transfected cells were irradiated at sublethal single doses. Cell proliferation was analyzed by nuclear cell counting. Apoptosis was detected using a fluorometric caspase-3 assay. Analysis of protein expression was accomplished by Western immunoblotting. Results: IR (10 Gy) reduced control U-87 cell proliferation by 40% through a caspase-independent mechanism. The overexpression of Survivin induced a cytoprotective effect against IR, while the overexpression of RhoA conferred a cytosensitizing effect upon IR. Control U-87 cells pretreated with EGCg exhibited a dose-dependent decrease in their proliferation rate. The growth inhibitory effect of EGCg was not antagonized by overexpressed Survivin. However, Survivin -transfected cells pretreated with EGCg became sensitive to IR, and their RhoA expression was downregulated. A potential therapeutic effect of EGCg targeting the prosurvival intracellular pathways of cancer cells is suggested to act synergistically with IR. Conclusion: The radioresistance of GBM is possibly mediated by a mechanism dependent on Survivin in conjunction with RhoA. The combination of natural anti-cancerous molecules such as EGCg with radiotherapy could improve the efficacy of IR treatments. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 64 条
[1]   Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts [J].
Ader, I ;
Delmas, C ;
Bonnet, J ;
Rochaix, P ;
Favre, G ;
Toulas, C ;
Cohen-Jonathan-Moyal, E .
ONCOGENE, 2003, 22 (55) :8861-8869
[2]   RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death [J].
Ader, I ;
Toulas, C ;
Dalenc, F ;
Delmas, C ;
Bonnet, J ;
Cohen-Jonathan, E ;
Favre, G .
ONCOGENE, 2002, 21 (39) :5998-6006
[3]  
Afra D, 2002, LANCET, V359, P1011
[4]   Survivin, versatile modulation of cell division and apoptosis in cancer [J].
Altieri, DC .
ONCOGENE, 2003, 22 (53) :8581-8589
[5]   Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase) [J].
Amano, M ;
Ito, M ;
Kimura, K ;
Fukata, Y ;
Chihara, K ;
Nakano, T ;
Matsuura, Y ;
Kaibuchi, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (34) :20246-20249
[6]   Probing the infiltrating character of brain tumors:: inhibition of RhoA/ROK-mediated CD44 cell surface shedding from glioma cells by the green tea catechin EGCg [J].
Annabi, B ;
Bouzeghrane, M ;
Moumdjian, R ;
Moghrabi, A ;
Béliveau, R .
JOURNAL OF NEUROCHEMISTRY, 2005, 94 (04) :906-916
[7]  
Annabi B, 2003, CANCER BIOL THER, V2, P642
[8]   Rho signals to cell growth and apoptosis [J].
Aznar, S ;
Lacal, JC .
CANCER LETTERS, 2001, 165 (01) :1-10
[9]  
Baatout S, 2004, ONCOL REP, V12, P159
[10]   Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme [J].
Baumann, F ;
Bjeljac, M ;
Kollias, SS ;
Baumert, BG ;
Brandner, S ;
Rousson, V ;
Yonekawa, Y ;
Bernays, RL .
JOURNAL OF NEURO-ONCOLOGY, 2004, 67 (1-2) :191-200